Homology Medicines Return on Equity

Homology Medicines posts a ROE of 39.09%. That is above the Healthcare sector average of 13.26%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 13.26% is typical. Homology Medicines's 39.09% is higher that level. That is roughly 194.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Homology Medicines's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 39.09%; use YoY and peer views to separate noise from signal.

Context for FIXX's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.26%), and (3) consistency with growth and profitability. This page covers the first two; Homology Medicines's other metric pages and overview cover the third.

Judging Homology Medicines against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 39.09% here, then scan peer and history charts to see if the gap is persistent.